SRR4296108
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
- ADIPOGENESIS+0.320
- FATTY_ACID_METABOLISM+0.310
- MYOGENESIS+0.290
- CHOLESTEROL_HOMEOSTASIS+0.280
- BILE_ACID_METABOLISM+0.270
- COAGULATION+0.220
- OXIDATIVE_PHOSPHORYLATION+0.220
- XENOBIOTIC_METABOLISM+0.220
- P53_PATHWAY+0.190
Top 10 suppressed
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.550
- PROTEIN_SECRETION-0.450
- MITOTIC_SPINDLE-0.380
- MYC_TARGETS_V1-0.360
- GLYCOLYSIS-0.300
- MTORC1_SIGNALING-0.240
- PI3K_AKT_MTOR_SIGNALING-0.240
- SPERMATOGENESIS-0.230
- NOTCH_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001515_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.840 |
| 2 | SJEPD025_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.809 |
| 3 | SJEPD039_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.804 |
| 4 | SRR5903552 | — | cohortA1 | 0.789 |
| 5 | BS_34201DKZ | Spinal Cord Ependymoma | — | 0.784 |
| 6 | SJEPD011_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.783 |
| 7 | BS_CVGFNCBJ | low-grade glioma | — | 0.778 |
| 8 | SRR29022836 | — | A | 0.774 |
| 9 | SJEPD028_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.771 |
| 10 | 60c210ff-d245-40d2-9de9-7b799cc3ffc9 | — | — | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.190 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |